Welcome to our dedicated page for X4 Pharmaceuticals SEC filings (Ticker: XFOR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
X4 Pharmaceuticals, Inc. filings document a rare-disease biopharmaceutical issuer with commercial activity for XOLREMDI and development work around mavorixafor. Its 8-K reports cover operating and financial results, material agreements, restructuring actions, executive and board changes, and capital-structure updates involving common stock, pre-funded warrants, registration rights, and equity purchase arrangements.
Proxy materials describe shareholder voting matters, board composition, committee assignments, executive compensation, equity awards, and governance procedures. The filing record also includes disclosures tied to the company’s inducement and equity incentive practices, financing arrangements, and formal reporting of material corporate events.
X4 Pharmaceuticals, Inc. reported that on August 22, 2025, directors David McGirr and R. Keith Woods resigned from its board of directors, including all board committees, effective immediately. The company stated that their resignations were not due to any disagreement regarding operations, policies, or practices.
Following these departures, Michael Wyzga was appointed chair of the board’s audit committee, and Francoise de Craecker and Gary Bridger were appointed as members of the audit committee, ensuring the committee remains staffed to oversee the company’s financial reporting and controls.
Biotechnology Value Fund and affiliated entities disclosed beneficial ownership stakes in X4 Pharmaceuticals (XFOR). Collectively certain Reporting Persons hold 2,243,659 shares, representing approximately 9.9% of the outstanding common stock on the filing date. Individually, BVF holds 1,168,649 shares (~5.2%), BVF2 holds 906,855 shares (~4.0%), and Biotechnology Value Trading Fund OS holds 123,369 shares (less than 1%). The reporting group also holds pre-funded warrants exercisable for an aggregate of 1,288,288 shares at $0.001 per share, subject to a blocker that limits current exercisable warrants to 9,917 shares for the Reporting Persons as of August 20, 2025. The filing clarifies shared voting and dispositive powers among fund entities, GP entities, Partners, BVF Inc. and Mark N. Lampert and includes a joint filing agreement as Exhibit 99.1.
Deep Track entities and David Kroin report beneficial ownership of 2,366,995 shares of X4 Pharmaceuticals (XFOR), representing 9.99% of the class. The filing shows shared voting and dispositive power over those shares and states the position was not acquired to change control. The beneficial-ownership calculation references the issuer's reported share counts and convertible instruments and notes the inclusion of 4,162,137 pre-funded warrants exercisable subject to a 9.99% maximum-percentage exercise limitation that prevents exercise if it would push ownership above 9.99%. The filing is a joint Schedule 13G by Deep Track Capital, LP; Deep Track Biotechnology Master Fund, Ltd.; and David Kroin and includes signatures dated August 19, 2025.
Trails Edge reports a 9.9% passive stake in X4 Pharmaceuticals. The filing shows Trails Edge Biotechnology Master Fund, LP directly holds 1,571,478 common shares and 745,675 shares underlying prefunded warrants, totaling 2,317,153 shares, which represent 9.9% of the outstanding common stock as of the Event Date. Trails Edge Capital Partners, LP (investment manager) and Ortav Yehudai (CIO) each may be deemed to beneficially own the same amount because of managerial and voting discretion. The filing discloses an issuance limitation that excludes 1,910,069 warrant shares from beneficial ownership calculations to avoid exceeding 9.99%.
Coastlands Capital and affiliated persons report acquiring a 9.99% beneficial ownership stake in X4 Pharmaceuticals (XFOR) following an August 2025 financing. The Reporting Persons hold an aggregate position equal to 2,479,645 shares of Common Stock on a fully‑diluted basis subject to a beneficial ownership blocker. Coastlands purchased a pre‑funded warrant exercisable for up to 7,047,216 shares for $9,999,999.50 and directly holds 107,500 shares purchased on August 12, 2025 for $1.7074 per share. The August 2025 Financing issued 11,040,776 shares and pre‑funded warrants to investors at $1.42 per share and $1.419 per pre‑funded warrant, respectively, and closed August 13, 2025. The Reporting Persons used working capital to fund their purchase, have registration rights for resale, and note Board changes at the Company including termination of the CEO and CFO and appointments of an Executive Chairman, new CFO and new President.
X4 Pharmaceuticals, Inc. received a Schedule 13D/A disclosing that Growth Equity Opportunities 18 VGE, LLC (GEO) and affiliated NEA entities participated in a private placement that closed on August 13, 2025. GEO purchased 1,734,184 shares of Common Stock at $1.42 per share and pre-funded warrants to acquire 5,311,810 shares at $1.419 each with a $0.001 exercise price, financed from GEO's working capital.
After the transaction GEO directly owns 2,233,744 shares and, taking into account exercisable pre-funded warrants and ownership limitations, has a total deemed ownership of 2,243,658 shares, representing 9.99% of the outstanding common stock based on 22,459,047 shares. The filing states the acquisition was for investment purposes and includes registration rights and related agreements filed by the issuer.
John Volpone, President and Director of X4 Pharmaceuticals, Inc. (XFOR), reported stock awards and option grants on 08/12/2025 and 08/14/2025. The Form 4 discloses 289,881 restricted stock units (RSUs) granted (zero purchase price) that vest one third on each of August 12, 2026, 2027 and 2028, subject to continued service and shareholder approval at the 2026 annual meeting. Two stock option grants were reported: 1,609,873 options at $1.42 (granted 08/12/2025) and 529,201 options at $3.14 (granted 08/14/2025). Each option vests one third on August 12, 2026 with the remainder vesting monthly over 24 months, contingent on continued service. The Form is filed by one reporting person and signed by attorney-in-fact.
Craig Adam R, serving as Executive Chairman and a Director of X4 Pharmaceuticals, Inc. (XFOR), filed an initial Form 3 dated 08/12/2025 reporting that he does not beneficially own any securities of the issuer. The filing includes an Exhibit 24 Power of Attorney and is signed on behalf of the reporting person by an attorney-in-fact on 08/14/2025.
X4 Pharmaceuticals, Inc. (XFOR) filed an initial Form 3 reporting that David Kirske holds the role of Chief Financial Officer and is a reporting person as of the 08/12/2025 event date. The filing states no securities are beneficially owned by the reporting person and lists an Exhibit 24 Power of Attorney. The submission is signed by an attorney-in-fact on 08/14/2025.
Craig Adam R, Executive Chairman and Director of X4 Pharmaceuticals, Inc. (XFOR), reported equity awards in a Form 4 covering transactions on 08/12/2025 and 08/14/2025. The filing shows 289,881 restricted stock units (RSUs) granted (vest one-third each year beginning 08/12/2026, contingent on service and shareholder approval at the 2026 annual meeting). The filing also reports two stock option grants: 1,609,873 options exercisable at $1.42 (vesting beginning 08/12/2026 with remaining vesting monthly over 24 months) and 529,201 options exercisable at $3.14 (granted 08/14/2025). After the reported transactions, the reporting person beneficially owns 289,881 shares and 1,609,873 and 529,201 underlying shares from options, all held directly.